Neuronoff, a medical device company developing minimally invasive neuromodulation solutions, has announced the completion of a first-in-human clinical trial for its Injectrode device, aimed at providing treatment for chronic pain.
The trial, known as the Lumbar Injectrode Feasibility Evaluation (LIFE) study, has reportedly met all its primary and secondary goals, demonstrating both safety and effectiveness.
The LIFE study involved ten participants who received the Injectrode, an injectable electrode, for a period of less than 30 days.
